7.2 Bipolar Disorder & Schizophrenia Spectrum

Bipolar Disorder & Schizophrenia Spectrum

Executive Summary: Bipolar Disorder and Schizophrenia Spectrum disorders represent severe, chronic psychiatric illnesses demanding precise pharmacological stabilization and rigorous ambulatory safety surveillance. For the Board Certified Ambulatory Care Pharmacist (BCACP), optimizing outcomes requires differentiating Bipolar I mania from Bipolar II hypomania, executing Therapeutic Drug Monitoring (TDM) and navigating treacherous drug interactions for classical mood stabilizers (lithium, valproic acid, lamotrigine), tracking metabolic and endocrine toxicities across Second-Generation Antipsychotics (SGAs), enforcing strict Clozapine REMS hematologic monitoring, treating extrapyramidal movement disorders, and rapidly distinguishing Neuroleptic Malignant Syndrome (NMS) from Serotonin Syndrome.

1. Diagnostic Staging: Bipolar I vs. Bipolar II & Schizophrenia Spectrum

Bipolar Disorder Classification

The DIG FAST Manic Symptom Mnemonic

A manic or hypomanic episode requires ≥3 of the following symptoms (≥4 if mood is only irritable):

• D — Distractibility: Attention easily drawn to irrelevant external stimuli.
• I — Indiscretion / Impulsivity: Excessive involvement in high-risk pleasurable activities (unrestrained buying sprees, sexual indiscretions, foolish business investments).
• G — Grandiosity: Inflated self-esteem or grandiose beliefs of special powers/talents.
• F — Flight of ideas: Subjective experience that thoughts are racing; rapid shifts between topics.
• A — Activity increase: Increased goal-directed activity (socially, at work, sexually) or psychomotor agitation.
• S — Sleep deficit: Decreased need for sleep (e.g., feels completely rested after only 2–3 hours of sleep).
• T — Talkativeness: Pressured speech; loud, rapid, and difficult to interrupt.

Schizophrenia Spectrum: Symptom Clusters

Schizophrenia requires ≥2 cardinal symptoms for ≥1 month (with signs of disturbance for ≥6 months), including at least one of delusions, hallucinations, or disorganized speech:

1. Positive Symptoms (Mesolimbic Hyperdopaminergia): Hallucinations (auditory most common), delusions (persecutory, referential, somatic), disorganized thought/speech, bizarre behavior. Highly responsive to D2 receptor antagonists.
2. Negative Symptoms (Mesocortical Hypodopaminergia): The "5 A's": Avolition (lack of motivation), Alogia (poverty of speech), Anhedonia (inability to experience pleasure), Asociality (social withdrawal), Affective flattening (blunted facial expression). Poorly responsive to typical antipsychotics; moderately addressed by SGAs.
3. Cognitive Symptoms (Dorsolateral Prefrontal Cortex): Deficits in executive function, working memory, attention, and processing speed.

2. Classical Mood Stabilizers: Lithium, Valproic Acid & Lamotrigine

Lithium: The Foundational Neuroprotective Mood Stabilizer

Lithium carbonate remains the gold standard for acute mania and maintenance in Bipolar I disorder, uniquely demonstrating proven reduction in suicide mortality.

+---------------------------------------------------------------------------------------+
|                         LITHIUM THERAPEUTIC DRUG MONITORING (TDM)                     |
+------------------------------------+--------------------------------------------------+
| Clinical Parameter                 | Therapeutic Target & Monitoring Protocol         |
+------------------------------------+--------------------------------------------------+
| Acute Mania Target Trough          | **0.8 to 1.2 mEq/L** (draw 12h post-evening dose)|
+------------------------------------+--------------------------------------------------+
| Maintenance Bipolar Target Trough  | **0.6 to 1.0 mEq/L** (elderly target 0.4-0.8)    |
+------------------------------------+--------------------------------------------------+
| Mild-to-Moderate Toxicity          | **1.5 to 2.0 mEq/L:** Coarse tremor, vomiting,   |
|                                    | diarrhea, ataxia, lethargy, muscle weakness.     |
+------------------------------------+--------------------------------------------------+
| Severe Toxicity Threshold          | **> 2.0 to 2.5 mEq/L:** Severe ataxia, dysarthria|
|                                    | blurred vision, hyperreflexia, clonus, delirium  |
+------------------------------------+--------------------------------------------------+
| Life-Threatening Toxicity          | **> 2.5 mEq/L:** Seizures, coma, arrhythmias,    |
|                                    | acute tubular necrosis, irreversible SILENT      |
|                                    | syndrome (cerebellar ataxia). **Hemodialysis**   |
|                                    | indicated if level >4.0 mEq/L (or >2.5 with Sx). |
+------------------------------------+--------------------------------------------------+

Crucial Lithium Drug-Drug & Physiological Interactions

Lithium is a monovalent cation filtered freely by the glomerulus, with 80% reabsorbed in the proximal renal tubule competing directly with sodium:

• Factors that INCREASE Lithium Levels (Risk of Toxicity):
  • Thiazide Diuretics (Hydrochlorothiazide, Chlorthalidone): Distal tubular sodium loss causes compensatory proximal sodium and lithium hyper-reabsorption (increases lithium levels by 25–40%).
  • NSAIDs (Ibuprofen, Naproxen, Meloxicam, Celecoxib): Inhibit renal vasodilatory prostaglandins, decreasing GFR and lithium clearance (Sulindac and Aspirin have lowest interaction).
  • ACE Inhibitors & ARBs (Lisinopril, Losartan): Decrease intraglomerular pressure and GFR, causing progressive lithium accumulation.
  • Dehydration, Fever, Vomiting, Low-Sodium Diets, Salt Restriction.
• Factors that DECREASE Lithium Levels (Loss of Efficacy):
  • Caffeine, Theophylline, Acetazolamide (carbonic anhydrase inhibitor), High dietary sodium intake.
• Mandatory Baseline & Periodic Monitoring: Serum BUN/Creatinine (nephrogenic diabetes insipidus, chronic interstitial nephritis), TSH and Free T4 (hypothyroidism, goiter), Serum Calcium (parathyroid hyperplasia), Baseline ECG (T-wave flattening, sinus node dysfunction), and Pregnancy Test (Ebstein's Anomaly cardiac tricuspid valve defect in 1st trimester).

Valproic Acid / Divalproex Sodium (Depakote)

• Therapeutic Range: 50 to 125 mcg/mL total trough concentration (bound + free). Highly protein-bound (~90%) to albumin with saturable binding kinetics.
• Four FDA Boxed Warnings:
  1. Fatal Hepatotoxicity: Highest risk during first 6 months and in children <2 years.
  2. Pancreatitis: Life-threatening hemorrhagic pancreatitis.
  3. Teratogenicity: Major congenital malformations, particularly Neural Tube Defects (Spina Bifida 1–2%) and long-term neurodevelopmental/IQ deficits. Avoid in women of childbearing potential.
  4. Mitochondrial Disease: Fatal liver failure in patients with POLG gene mutations.
• Other Adverse Effects: Dose-dependent thrombocytopenia (monitor CBC), hyperammonemic encephalopathy (treat with L-carnitine if symptomatic despite normal LFTs), alopecia, weight gain, tremor.

Lamotrigine (Lamictal): Bipolar Depression Maintenance

• Role in Bipolar Therapy: Highly effective for maintenance and prevention of Bipolar Depression (ineffective for acute mania).
• Boxed Warning: Severe, potentially life-threatening cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
• Mandatory Slow Titration Protocol (Standard Starter Kit):
  • Weeks 1–2: 25 mg orally once daily.
  • Weeks 3–4: 50 mg orally once daily.
  • Week 5: 100 mg orally once daily.
  • Week 6+: Titrate to 200 mg orally once daily.
  • Re-titration Rule: If therapy is interrupted for > 5 half-lives (≥ 4 to 5 days), the slow titration schedule must be restarted from the 25 mg baseline.
• The Valproate Interaction (50% Dose Cut): Valproate inhibits lamotrigine glucuronidation (UGT1A4/2B7), doubling lamotrigine's half-life from ~24 hours to ~60 hours. Co-administration doubles SJS/TEN risk; must use the Blue Starter Kit (25 mg every other day for weeks 1–2, 25 mg daily for weeks 3–4, 50 mg daily for week 5, 100 mg daily target).

3. Second-Generation Antipsychotics (SGAs) & Clozapine REMS

Second-Generation (Atypical) Antipsychotics block postsynaptic dopamine D2 receptors and serotonin 5-HT2A receptors. 5-HT2A antagonism stimulates downstream dopamine release in the nigrostriatal pathway (mitigating EPS) and mesocortical pathway (improving negative and affective symptoms).

Metabolic, Endocrine & Cardiovascular Stratification

ADA / APA Metabolic Monitoring Consensus Protocol

For all patients receiving SGAs, obtain:

1. BMI & Weight: Baseline, 4 weeks, 8 weeks, 12 weeks, then quarterly.
2. Blood Pressure: Baseline, 12 weeks, then annually.
3. Fasting Plasma Glucose / HbA1c: Baseline, 12 weeks, then annually.
4. Fasting Lipid Profile: Baseline, 12 weeks, then every 5 years (or every 6–12 months if dyslipidemic).

Clozapine (Clozaril) REMS Architecture & Boxed Warnings

Clozapine is the only agent with proven superiority for Treatment-Resistant Schizophrenia (failure of ≥2 adequate trials of antipsychotics) and Suicidality in Schizophrenia.

Five Critical FDA Boxed Warnings

1. Severe Neutropenia / Fatal Agranulocytosis.
2. Myocarditis and Cardiomyopathy (highest in first 4–6 weeks; check baseline troponin/CRP).
3. Severe Gastrointestinal Hypomotility / Bowel Obstruction (potent anticholinergic effect leading to paralytic ileus, toxic megacolon, and death).
4. Dose-Dependent Seizures (threshold >600 mg/day; manage with valproate).
5. Orthostatic Hypotension, Bradycardia, and Syncope.

Clozapine REMS Hematologic Monitoring Table

• Mild Neutropenia (ANC 1,000–1,499 /uL): Continue clozapine, monitor ANC 3 times per week.
• Moderate Neutropenia (ANC 500–999 /uL): Interrupt clozapine therapy immediately, obtain daily ANC until ≥1,000 /uL, then resume.
• Severe Agranulocytosis (ANC < 500 /uL): Discontinue clozapine permanently; do NOT rechallenge.

4. Life-Threatening Emergencies: NMS vs. Serotonin Syndrome

Ambulatory care pharmacists must immediately differentiate Neuroleptic Malignant Syndrome (NMS) from Serotonin Syndrome (SS) in patients presenting with altered mental status and autonomic instability.

Comprehensive Diagnostic Comparison Table